Evofem Biosciences (EVFM) Q1 2026 earnings summary

Executive summary

• Commercial portfolio includes PHEXX (non-hormonal contraceptive gel) and SOLOSEC (single-dose antimicrobial for BV and trichomoniasis), with SOLOSEC acquired in July 2024 and relaunched in November 2024.

• Advanced global commercialization strategy with new distribution agreements in Sub-Saharan Africa and ongoing regulatory reviews in the UAE for key products.

• Net product sales for Q1 2026 were $899K, up 6% year-over-year, driven by higher WAC for PHEXX and increased SOLOSEC sales, partially offset by lower PHEXX volume.

• Company faces significant liquidity challenges, with a $72.7M working capital deficit and $902.9M accumulated deficit as of March 31, 2026.

• Management has concluded there is substantial doubt about the ability to continue as a going concern without additional funding.

Financial highlights

• Net loss for Q1 2026 was $5.5M, or $(0.04) per share, compared to net income of $1.0M, or $0.01 per share, in Q1 2025, primarily due to the absence of one-time R&D expense reductions seen in the prior year.

• Net sales for Q1 2026 were $0.9 million, up from $0.8 million year-over-year, driven by higher WAC, improved gross-to-net ratios, and increased SOLOSEC ex-factory sales.

• Cost of goods sold increased 12% to $410K, mainly due to write-off of expired raw materials.

• Cash and cash equivalents at quarter-end were $1.5M, including $0.9M restricted.

• Total current liabilities were $78.8M, with a stockholders' deficit of $77.6M as of March 31, 2026.

Outlook and guidance

• Management plans to focus on top-line growth, maintain a lean cost structure, and seek additional funding through product sales, restructuring payables, and potential equity or debt financings.

• Strategic priorities include expanding PHEXX and SOLOSEC access, pursuing ex-U.S. partnerships, and exploring new market opportunities.

• Anticipates non-dilutive capital from ex-U.S. markets in 2026 through new alliances.

• Expects continued progress in regulatory approvals and commercial launches outside the U.S.